| 货号 | 规格 | 价格 | 上海 | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|
S81266-1mg |
98.3% | ￥120.00 | 9 | - | - | - |
|
S81266-5mg |
98.3% | ￥194.00 | >10 | - | - | - |
|
S81266-10mg |
98.3% | ￥330.00 | >10 | - | - | - |
|
S81266-25mg |
98.3% | ￥660.00 | >10 | - | - | - |
|
S81266-50mg |
≥98% | ￥1120.00 | 货期：2-3天 | - | - | - |
|
S81266-100mg |
≥98% | ￥1910.00 | 货期：2-3天 | - | - | - |
|
CP21R7 is potent GSK-3β inhibitor, with an IC50 of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC50 of 1900 nM.
| 产品描述： | CP21R7 is potent GSK-3β inhibitor, with an IC50 of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC50 of 1900 nM. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | GSK-3β:1.8 nM (IC50);PKCα:1900 nM (IC50);GSK-3; PKC | ||||||||||||||||||||
| 体外研究： | CP21R7 (Compound 9) is a selective inhibitor of GSK-3β, with an IC50 of 1.8 nM; the IC50 of CP21R7 against PKCα is 1900 nM. CP21R7 (CP21, 3 μM) potently activates canonical Wnt signaling with highest activity. CP21 significantly increases total levels of intracellular β-catenin. CP21 combined with BMP4 induces commitment of hPSCs towards mesoderm | ||||||||||||||||||||
| 参考文献： | 1. Gong L, et al. Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6. 2. Patsch C, et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol. 2015 Aug;17(8):994-1003. | ||||||||||||||||||||
| 溶解性： | soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京